Liver Cirrhosis Clinical Trial
Official title:
Randomized Trial, Masked, and Placebo Controlled to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension
The purpose of this study is to determine whether sapropterin (an oral analogue of tetrahydrobiopterin) could have a role in the treatment of portal hypertension secondary to liver cirrhosis. Sapropterin or placebo will be given for two weeks in patients with liver cirrhosis and clinically significant portal hypertension. Systemic and hepatic hemodynamics studies will be performed at baseline and after the intervention to assess the effect of sapropterin.
Portal hypertension and its complications (variceal bleeding, encephalopathy, spontaneous
bacterial peritonitis, hepatorenal syndrome) are the main cause of death and liver
transplantation in patients with cirrhosis. Diminishing portal hypertension by drugs
(beta-blockers) is associated with a protection in the development of complications from
portal hypertension. For this reason it is important to investigate and develop drugs that
can reduce the portal pressure in liver cirrhosis. Tetrahydrobiopterin has been shown to
decrease portal pressure in animal models of cirrhosis by improving intrahepatic resistance
and by increasing nitric oxide bioavailability (eNOS co-factor). These effects were not
associated to deleterious effects on systemic hemodynamics.
This study aims to test if sapropterin (an oral analogue of tetrahydrobiopterin) can play a
role in the management of portal hypertension. For this, patients with liver cirrhosis and
clinically significant portal hypertension will be randomized to receive sapropterin or
placebo for two weeks. Patients will undergo an hepatic vein catheterization to asses the
hepatic venous pressure gradient (HVPG), and those having and HVPG of 10 mmHg or higher will
be randomized to receive sapropterin or placebo. Swan-Ganz catheterization, systemic
measurements, and hepatic blood flow by indocyanine green method will also be performed.
Patients will receive sapropterin or placebo for two weeks at a dosage of 5 mg/kg/d in the
first week, increasing to 10 mg/kg/d in the second week if there are no adverse events or
intolerance. A second systemic and hepatic hemodynamic study will be performed after 2 weeks
of treatment to assess changes.
Changes in laboratory tests, liver function (Child-Pugh and MELD scores), endothelial
dysfunction and oxidative stress markers (Von Willebrand Factor, Malondialdehyde) will be
monitored during the study. As sapropterin has been never evaluated in cirrhotic patients,
tolerance and adverse effects related to the medication will be registered.
The study will be stratified according to previous beta-blocker therapy (receiving or not
receiving beta-blockers).
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04533932 -
Endosonographic Shear Wave Elastography for Liver Stiffness
|
||
Not yet recruiting |
NCT06031740 -
A Comparison of Flexible Endoscopic Polidocanol Liquid and Foam Sclerotherapy in Cirrhotic Patients With Bleeding From Internal Hemorrhoids
|
N/A | |
Not yet recruiting |
NCT06026267 -
Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis
|
N/A | |
Not yet recruiting |
NCT06076330 -
Efficacy of 5% Albumin v/s Plasmalyte in Combination With 20% Albumin for Fluid Resuscitation in Cirrhosis With Sepsis Induced Hypotension
|
N/A | |
Enrolling by invitation |
NCT05055713 -
A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism
|
N/A | |
Recruiting |
NCT04578301 -
Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
|
||
Not yet recruiting |
NCT05515861 -
Evaluation of EUS in Preventing Rebleeding After Endoscopic Cyanoacrylate Injection for Gastric Varices
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Not yet recruiting |
NCT02710227 -
Sleep Timing and Circadian Preferences in A Sample of Egyptian Patients With Hepatic Cirrhosis
|
N/A | |
Not yet recruiting |
NCT03623360 -
Functional MRI to Determine Severity of Cirrhosis
|
||
Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
Active, not recruiting |
NCT02551250 -
Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis
|
||
Recruiting |
NCT02239991 -
Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant
|
N/A | |
Enrolling by invitation |
NCT02256514 -
Open Label Trial of Immunotherapy for Advanced Liver Cancer
|
Phase 2 | |
Terminated |
NCT02311985 -
Comparison of Three Transfusion Strategies for Central Venous Catheterization in Cirrhotics: A Randomized Clinical Trial
|
N/A | |
Terminated |
NCT01937130 -
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
|
Phase 2 | |
Recruiting |
NCT01724697 -
Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01728727 -
Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01728688 -
Safety and Efficacy of Human Autologous Peripheral Blood Stem Cells for Treatment of HBV-related Liver Cirrhosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01618890 -
Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding
|
Phase 3 |